LYRAX | VMVAX | LYRAX / VMVAX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 2 years | 13 years | - |
Gain YTD | 15.324 | 14.946 | 103% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 3000 | 33% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 876M | 30.5B | 3% |
Annual Yield % from dividends | 0.37 | 2.14 | 17% |
Returns for 1 year | 32.38 | 25.35 | 128% |
Returns for 3 years | N/A | 20.71 | - |
Returns for 5 years | N/A | 48.82 | - |
Returns for 10 years | N/A | 100.88 | - |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
MART | 32.71 | -0.02 | -0.05% |
AllianzIM U.S. Large Cp Buffer10 Mar ETF | |||
SBIO | 38.79 | -0.13 | -0.33% |
ALPS Medical Breakthroughs ETF | |||
RPV | 88.57 | -0.82 | -0.92% |
Invesco S&P 500® Pure Value ETF | |||
MDEV | 21.73 | -0.20 | -0.93% |
First Trust Indxx Global Mdcl Dvcs ETF | |||
ARGT | 69.39 | -0.76 | -1.08% |
Global X MSCI Argentina ETF |